Abstract
Bevacizumab which is a humanized murine monoclonal antibody against vascular endothelial growth factor, given in combination with carboplatin and paclitaxel, was granted a labeling extension treatment of advanced-stage Non-Small Cell Lung Cancer (NSCLC). Common toxic effects include hypertension, proteinuria, and neutropenia. Rare complications include bleeding, particularly hemoptysis, and surgical wound dehiscence, but pneumothorax in NSCLC is rare. We report a case of persistent pneumothorax related to bevacizumab in a patient with NSCLC. *Corresponding author: Hidefumi Koh, Division of Pulmonary Medicine, Department of Internal Medicine, Saiseikai Utsunomiya Hospital, 911-1 Takebayashimachi, Utsunomiya-shi, Tochigi 321-0974, Japan, Tel: +81-28-6265500; Fax: +81-28-626-5594; E-mail: hdfmkoh@yahoo.com Received January 13, 2013; Accepted March 25, 2013; Published March 26, 2013 Citation: Koh H, Kamiishi N, Kimura Y, Tajima A, Yagami T, et al. (2013) A Rare Case of Persistent Pneumothorax in Non-Small Cell Lung Cancer on Bevacizumab Therapy. J Pulmon Resp Med S14: 001. doi:10.4172/2161-105X.S14-001 Copyright: © 2013 Koh H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Highlights
Bevacizumab is used as a standard regimen for chemotherapy in patients with Non-small cell lung cancer (NSCLC) [1,2]
Peumothorax occurring after Bevacizumab-containing chemotherapy in NSCLC has been rarely described [3]
Pneumothorax related to bevacizumab has been rarely described [3]
Summary
Bevacizumab is used as a standard regimen for chemotherapy in patients with Non-small cell lung cancer (NSCLC) [1,2]. 54-year-old man was admitted in March 2010 to our hospital because of dyspnea and right pleural effusion. He had smoked three packs of cigarettes per day for thirty four years. Chest X-ray showed right pleural effusion (Figure 1A). To control malignant pleural effusion, chemical pleurodesis was performed. He administered two cycles of Cisplatin (CDDP) with Pemetrexed as first-line chemotherapy. It was not effective so that second-line chemotherapy of Carboplatin (CBDCA), Paclitaxel (PTX) with Bevacizumab was administered and continued six cycles. Chest CT after second-line chemotherapy showed right pneumothorax with pleural. Pneumothorax with pleural adhesion persisted, but his respiratory failure did not worsened.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
